Ignite Creation Date:
2025-12-25 @ 2:30 AM
Ignite Modification Date:
2025-12-26 @ 1:06 AM
Study NCT ID:
NCT03459534
Status:
RECRUITING
Last Update Posted:
2024-10-28
First Post:
2018-02-12
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Sponsor:
Il-Yang Pharm. Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-06-25
Start Date Type:
ACTUAL
Primary Completion Date:
2026-06-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2018-02-12
First Submit QC Date:
None
Study First Post Date:
2018-03-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-24
Last Update Post Date:
2024-10-28
Last Update Post Date Type:
ACTUAL